Ankylosing spondylitis patients commencing biologic therapy have high baseline levels of comorbidity: a report from the Australian rheumatology association database
- PMID: 20107564
- PMCID: PMC2809318
- DOI: 10.1155/2009/268569
Ankylosing spondylitis patients commencing biologic therapy have high baseline levels of comorbidity: a report from the Australian rheumatology association database
Abstract
Aims. To compare the baseline characteristics of a population-based cohort of patients with ankylosing spondylitis (AS) commencing biological therapy to the reported characteristics of bDMARD randomised controlled trials (RCTs) participants. Methods. Descriptive analysis of AS participants in the Australian Rheumatology Association Database (ARAD) who were commencing bDMARD therapy. Results. Up to December 2008, 389 patients with AS were enrolled in ARAD. 354 (91.0%) had taken bDMARDs at some time, and 198 (55.9%) completed their entry questionnaire prior to or within 6 months of commencing bDMARDs. 131 (66.1%) had at least one comorbid condition, and 24 (6.8%) had a previous malignancy (15 nonmelanoma skin, 4 melanoma, 2 prostate, 1 breast, cervix, and bowel). Compared with RCT participants, ARAD participants were older, had longer disease duration and higher baseline disease activity. Conclusions. AS patients commencing bDMARDs in routine care are significantly different to RCT participants and have significant baseline comorbidities.
Figures
Similar articles
-
Baseline comorbidities in a population-based cohort of rheumatoid arthritis patients receiving biological therapy: data from the Australian rheumatology association database.Int J Rheumatol. 2009;2009:861481. doi: 10.1155/2009/861481. Epub 2009 Sep 1. Int J Rheumatol. 2009. PMID: 20130803 Free PMC article.
-
Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort study.BMC Musculoskelet Disord. 2015 Oct 20;16:309. doi: 10.1186/s12891-015-0772-2. BMC Musculoskelet Disord. 2015. PMID: 26481039 Free PMC article.
-
Comparison of comorbidities and treatment between ankylosing spondylitis and non-radiographic axial spondyloarthritis in the United States.Rheumatology (Oxford). 2019 Nov 1;58(11):2025-2030. doi: 10.1093/rheumatology/kez171. Rheumatology (Oxford). 2019. PMID: 31081033 Free PMC article.
-
Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.Pharmacoeconomics. 2018 Sep;36(9):1063-1072. doi: 10.1007/s40273-018-0639-0. Pharmacoeconomics. 2018. PMID: 29546668 Review.
-
Consensus development on eligibility of government subsidisation of biologic disease modifying anti-rheumatic agents for treatment of ankylosing spondylitis: The Singapore experience.Int J Rheum Dis. 2017 Oct;20(10):1517-1526. doi: 10.1111/1756-185X.12707. Epub 2015 Jul 14. Int J Rheum Dis. 2017. PMID: 26177789 Review.
Cited by
-
Indirect comparison between subcutaneous biologic agents in ankylosing spondylitis.Clin Drug Investig. 2015 Jan;35(1):23-9. doi: 10.1007/s40261-014-0246-6. Clin Drug Investig. 2015. PMID: 25388909
-
A Pilot Study to Assess the Feasibility of a Web-Based Survey to Examine Patient-Reported Symptoms and Satisfaction in Patients with Ankylosing Spondylitis Receiving Secukinumab.Drugs Real World Outcomes. 2019 Jun;6(2):83-91. doi: 10.1007/s40801-019-0154-4. Drugs Real World Outcomes. 2019. PMID: 31054047 Free PMC article.
-
Insight into the Quality of Life of Patients with Ankylosing Spondylitis: Real-World Data from a US-Based Life Impact Survey.Rheumatol Ther. 2019 Sep;6(3):353-367. doi: 10.1007/s40744-019-0160-8. Epub 2019 May 20. Rheumatol Ther. 2019. PMID: 31111433 Free PMC article.
-
Pain management for inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and other spondylarthritis) and gastrointestinal or liver comorbidity.Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD008951. doi: 10.1002/14651858.CD008951.pub2. Cochrane Database Syst Rev. 2012. PMID: 22258995 Free PMC article.
-
Cost effectiveness of therapeutic interventions in ankylosing spondylitis: a critical and systematic review.Pharmacoeconomics. 2012 Dec 1;30(12):1145-56. doi: 10.2165/11596490-000000000-00000. Pharmacoeconomics. 2012. PMID: 23098324
References
-
- British Society for Rheumatology. BSR guideline for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. December 2005, http://www.rheumatology.org.uk. - PubMed
-
- Davis JC, van der Heijde D, Dougados M, Woolley JM. Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy. Arthritis Care and Research. 2005;53(4):494–501. - PubMed
-
- Ward MM. Health-related quality of life in ankylosing spondylitis: a survey of 175 patients. Arthritis Care and Research. 1999;12(4):247–255. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials